PMID- 20641106
OWN - NLM
STAT- MEDLINE
DCOM- 20101026
LR  - 20211020
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 33
IP  - 7
DP  - 2010 Jul
TI  - Clinical features of the dilated phase of hypertrophic cardiomyopathy in 
      comparison with those of dilated cardiomyopathy.
PG  - E24-8
LID - 10.1002/clc.20533 [doi]
AB  - BACKGROUND: Although the dilated phase of hypertrophic cardiomyopathy (D-HCM) 
      characterized by left ventricular (LV) systolic dysfunction and cavity dilatation 
      has been reported to be a poor prognosis, this is now in contrast to the improved 
      prognosis of dilated cardiomyopathy (DCM) in the era of advancements in heart 
      failure management. There has been no investigation of the clinical features of 
      D-HCM compared with those of DCM from the point of management of systolic 
      dysfunction. HYPOTHESIS: The aim of this study was to investigate the clinical 
      features of D-HCM in comparison with those of DCM in a single institute. METHODS: 
      We studied 20 consecutive patients with D-HCM (global ejection fraction < 50%) 
      and 115 consecutive patients with DCM. RESULTS: At diagnosis of D-HCM, 8 (40%) of 
      the D-HCM patients already experienced dyspnea (New York Heart Association [NYHA] 
      class >or= III). Left atrial diameter was larger and prevalence of atrial 
      fibrillation was higher in the D-HCM group, although LV size was larger and LV 
      ejection fraction was lower in the DCM group. During the follow-up period (4.0 
      years), 11 (55%) of the patients with D-HCM died. The 5-year survival rate from 
      all-cause mortality including cardiac transplantation was 45.6% in patients with 
      D-HCM vs 81.6% in patients with DCM (log-rank P = .0001). CONCLUSIONS: Patients 
      with D-HCM were more symptomatic at diagnosis, although LV dilatation and 
      impaired fractional shortening seemed more severe in patients with DCM. The 
      prognosis for D-HCM patients was worse than that for patients with DCM despite 
      similar or even more intensive treatment for heart failure.
CI  - Copyright (c) 2010 Wiley Periodicals, Inc.
FAU - Hamada, Tomoyuki
AU  - Hamada T
AD  - Department of Medicine and Geriatrics, Kochi Medical School, Nankoku-shi, Kochi, 
      Japan.
FAU - Kubo, Toru
AU  - Kubo T
FAU - Kitaoka, Hiroaki
AU  - Kitaoka H
FAU - Hirota, Takayoshi
AU  - Hirota T
FAU - Hoshikawa, Eri
AU  - Hoshikawa E
FAU - Hayato, Kayo
AU  - Hayato K
FAU - Shimizu, Yuji
AU  - Shimizu Y
FAU - Okawa, Makoto
AU  - Okawa M
FAU - Yamasaki, Naohito
AU  - Yamasaki N
FAU - Matsumura, Yoshihisa
AU  - Matsumura Y
FAU - Yabe, Toshikazu
AU  - Yabe T
FAU - Takata, Jun
AU  - Takata J
FAU - Doi, Yoshinori L
AU  - Doi YL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
SB  - IM
MH  - Adult
MH  - Aged
MH  - Atrial Fibrillation/etiology
MH  - Cardiomyopathy, Dilated/*complications/mortality/physiopathology/therapy
MH  - Cardiomyopathy, Hypertrophic/*complications/mortality/physiopathology/therapy
MH  - Chi-Square Distribution
MH  - Disease Progression
MH  - Dyspnea/etiology
MH  - Female
MH  - Heart Failure/*etiology/mortality/physiopathology/therapy
MH  - Heart Transplantation
MH  - Humans
MH  - Japan
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Risk Assessment
MH  - Risk Factors
MH  - Stroke Volume
MH  - Survival Rate
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ventricular Dysfunction, Left/*etiology/mortality/physiopathology/therapy
MH  - *Ventricular Function, Left
MH  - Ventricular Remodeling
PMC - PMC6652988
EDAT- 2010/07/20 06:00
MHDA- 2010/10/27 06:00
PMCR- 2010/03/31
CRDT- 2010/07/20 06:00
PHST- 2010/07/20 06:00 [entrez]
PHST- 2010/07/20 06:00 [pubmed]
PHST- 2010/10/27 06:00 [medline]
PHST- 2010/03/31 00:00 [pmc-release]
AID - CLC20533 [pii]
AID - 10.1002/clc.20533 [doi]
PST - ppublish
SO  - Clin Cardiol. 2010 Jul;33(7):E24-8. doi: 10.1002/clc.20533.